
-
'Incredible' Curry scores 52 as Warriors down Grizzlies, Bucks edge Suns
-
Asian markets edge up but uncertainty rules ahead of Trump tariffs
-
Nintendo's megahit Switch console: what to know
-
Nintendo to unveil upgrade to best-selling Switch console
-
China practises hitting key ports, energy sites in Taiwan drills
-
Oil, sand and speed: Saudi gearheads take on towering dunes
-
All eyes on Tsunoda at Japan GP after ruthless Red Bull move
-
'Image whisperers' bring vision to the blind at Red Cross museum
-
Hay shines as New Zealand make 292-8 in Pakistan ODI
-
Other governments 'weaponising' Trump language to attack NGOs: rights groups
-
UK imposes online entry permit on European visitors
-
How a Brazilian chief is staving off Amazon destruction
-
Meme politics: White House embraces aggressive alt-right online culture
-
China launches military drills in Taiwan Strait
-
US senator smashes record with 25-hour anti-Trump speech
-
Brazil binman finds newborn baby on garbage route
-
US senator smashes record with marathon anti-Trump speech
-
Trump advisor Waltz faces new pressure over Gmail usage
-
Niger junta frees ministers of overthrown government
-
Trump set to unleash 'Liberation Day' tariffs
-
Boeing chief to acknowledge 'serious missteps' at US Senate hearing
-
Real Madrid hold Real Sociedad in eight-goal thriller to reach Copa del Rey final
-
Nuno salutes 'special' Elanga after stunning strike fires Forest
-
PSG survive scare against Dunkerque to reach French Cup final
-
Sundowns edge Esperance as crowd violence mars quarter-final
-
Nottingham Forest beat Man Utd, Saka scores on Arsenal return
-
Elanga wonder-goal sinks Man Utd as Forest eye Champions League berth
-
Stock markets mostly advance ahead of Trump tariffs deadline
-
US movie theaters urge 45-day 'baseline' before films hit streaming
-
Saka scores on return as Arsenal beat Fulham
-
Third-division Bielefeld shock holders Leverkusen in German Cup
-
Ball-blasting 'Torpedo bats' making waves across MLB opening weekend
-
Newsmax shares surge more than 2,000% in days after IPO
-
Thousands of Hungarians protest against Pride ban law
-
GM leads first quarter US auto sales as tariffs loom
-
Tesla sales tumble in Europe in the first quarter
-
No 'eye for an eye' approach to US tariffs: Mexico
-
NFL club owners back dynamic kickoffs, delay tush push vote
-
Trump 'perfecting' new tariffs as nervous world braces
-
Trump nominee says to press UK on Israel arms
-
French court says Le Pen appeal ruling could come before presidential vote
-
The battle to control assets behind Bosnia crisis
-
Prabhsimran powers Punjab to IPL win over Lucknow
-
Mass layoffs targeting 10,000 jobs hit US health agencies
-
Tiger's April Foolishness: plan to play Masters just a joke
-
Myanmar quake toll passes 2,700, nation halts to honour victims
-
Turkish fans, artists urge Muse to cancel Istanbul gig
-
US seeks death penalty for accused killer of insurance CEO
-
UK govt moves to block sentencing guidelines for minority defendants
-
Trump puts world on edge as 'Liberation Day' tariffs loom

Has there finally been progress in treating schizophrenia?
For decades there has been almost no improvement in the medical treatment of schizophrenia, one of the most serious and devastating of all mental illnesses, but recent advances have raised hopes of progress.
The condition often only hits the headlines after violent attacks by sufferers, such as a schizophrenic patient who stabbed a nurse to death last week in the French city of Reims.
But French psychiatrist Sonia Dollfus emphasised that such cases of violence by people with schizophrenia are "extremely rare".
"All the work done over the years trying to de-stigmatise this disease -- it is swept away in 24 hours," Dollfus told AFP.
Around one in every 300 people worldwide are affected by schizophrenia, according to the World Health Organization.
It causes a wide range of distressing delusional disorders, which vary in intensity between patients but often hugely disrupts their lives.
At least five percent of schizophrenia patients are estimated to die by suicide.
The condition is usually treated with a combination of anti-psychotic drugs, social support for reintegration, and psychological therapy.
Scottish psychiatrist Robin Murray, who has spent decades researching schizophrenia, told AFP that when it came to medication, "treatment has not changed dramatically" over the last 20 or 30 years.
He added that psychological therapy had improved in that time.
But unlike numerous other mental disorders -- particularly neurotic conditions -- taking serious drugs remains the cornerstone in treating schizophrenia.
- Innovation -
For drugs, there has been a "blank period since the 2010s, when pharmaceutical laboratories really withdrew from psychiatry," Dollfus said.
But there has been some innovation recently, she added.
One development have been apps that can track patients' progress, ensure timely follow-up sessions and contact psychiatrists if necessary.
Another is a new treatment approved by the US Food and Drug Administration last month.
The treatment, developed by the Israeli pharmaceutical firm Teva and France's MedinCell, involves the drug risperidone which has long been used for schizophrenia.
It has traditionally been prescribed as a daily pill, but the new treatment is administered via injection, allowing the drug to be gradually released in the body over several weeks.
This makes it impossible for patients to miss a daily pill.
Interruptions to medication, often brought about by the psychosis the illness causes, are a common problem in treating schizophrenia.
For example, the attacker in Reims had been off his medication, according to several sources.
- 'Really promising' -
This new way of administering an old medication is not the kind of revolution that a new drug would represent. But progress may soon be made in that area.
Dollfus said that some drugs currently being investigated are "really interesting" because they work in a different way than those of the past.
Traditionally, anti-psychotic drugs used to treat schizophrenia aim to block the action of dopamine, a molecule that acts as a chemical messenger in the brain.
However, dopamine seems to play a complex role in schizophrenia -- some patients can have excessive levels in some respects and insufficient levels in others.
Traditional anti-psychotic drugs, which tend to work well at stopping certain symptoms such as hallucinations, do not help in other areas, such as the loss of willpower or struggles with language and speech.
Recent research has focused on finding other molecules which regulate rather than block dopamine, while also acting on other areas thought to be involved in schizophrenia.
These treatments, such as one that targets a protein called TAAR1, are still some way away from being available to patients.
But the TAAR1 drug has had positive results from the most advanced stage of trials, known as phase 3.
"This is a really promising avenue," Dollfus said.
M.Fischer--AMWN